Last reviewed 2026-05-18 · How we verify

dose-escalated selinexor treatment

Sheba Medical Center · Phase 1 active Small molecule Quality 55/100

dose-escalated selinexor treatment is a XPO1 inhibitor Small molecule drug developed by Sheba Medical Center. It is currently in Phase 1 development. Also known as: KPT-330.

Selinexor blocks XPO1 (exportin-1), preventing nuclear export of tumor suppressor proteins and causing cancer cell death.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	dose-escalated selinexor treatment
Also known as	KPT-330
Sponsor	Sheba Medical Center
Drug class	XPO1 inhibitor
Modality	Small molecule
Phase	Phase 1

Mechanism of action

Selinexor selectively inhibits XPO1, a nuclear export protein that transports tumor suppressor proteins, growth regulators, and mRNAs out of the cell nucleus. By blocking XPO1, selinexor forces nuclear retention and activation of tumor suppressor proteins, leading to cancer cell apoptosis while sparing normal cells.

Approved indications

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

dose-escalated selinexor treatment CI brief — competitive landscape report
dose-escalated selinexor treatment updates RSS · CI watch RSS
Sheba Medical Center portfolio CI

Frequently asked questions about dose-escalated selinexor treatment

What is dose-escalated selinexor treatment?

dose-escalated selinexor treatment is a XPO1 inhibitor drug developed by Sheba Medical Center.

How does dose-escalated selinexor treatment work?

Selinexor blocks XPO1 (exportin-1), preventing nuclear export of tumor suppressor proteins and causing cancer cell death.

Who makes dose-escalated selinexor treatment?

dose-escalated selinexor treatment is developed by Sheba Medical Center (see full Sheba Medical Center pipeline at /company/sheba-medical-center).

Is dose-escalated selinexor treatment also known as anything else?

dose-escalated selinexor treatment is also known as KPT-330.

What drug class is dose-escalated selinexor treatment in?

dose-escalated selinexor treatment belongs to the XPO1 inhibitor class. See all XPO1 inhibitor drugs at /class/xpo1-inhibitor.

What development phase is dose-escalated selinexor treatment in?

dose-escalated selinexor treatment is in Phase 1.

Drug class: All XPO1 inhibitor drugs
Manufacturer: Sheba Medical Center — full pipeline
Also known as: KPT-330

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing